Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostemsavir in HIV Immunologic Non-responders
NCT05220358Phase 4Active, not recruiting
- Sponsor
- Orlando Immunology Center
- Start
- Jun 2022
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fostemsavir in human immunodeficiency virus infection (HIV), sponsored by Orlando Immunology Center. Started Jun 2022; status: active, not recruiting.
02
Drugs
fostemsavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05220358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05220358.